MGMark Garzotto

Mark Garzotto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Garzotto has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

    by Oliver Sartor, Theodore G. Karrison, Howard M. Sandler, Leonard G. Gomella, Mahul B. Amin, James Purdy, Jeff M. Michalski, Mark G. Garzotto, Nadeem Pervez, Alexander G. Balogh, et al.


  • Open Access

    Dairy Product Consumption and Prostate Cancer Risk in the United States

    by Isabella Preble, Zhenzhen Zhang, Ryan Kopp, Mark Garzotto, Gerd Bobe, Jackilen Shannon, Yumie Takata

    An ongoing controversy exists regarding the effect of dairy products on prostate cancer risk in observational studies. We prospectively investigated the associations between dairy product consumption and prostate cancer risk among men in the United States. After calculating pre-diagnostic intake of individual or subgroups of dairy products using a validated food frequency questionnaire, we estimated hazard ratios (HR) and 95% confidence intervals (CI) for pathologically-verified cases of incident prostate cancer among men, overall, or stratified by severity. Among 49,472 men, 4134 were diagnosed with prostate cancer during an average follow-up period of 11.2 years. The median total dairy intake was 101 g/1000 kcal. Consumption of total, individual, or subgroups of dairy products was not statistically significantly associated with prostate cancer risk overall (HR = 1.05, 95% CI = 0.96–1.15 comparing the highest with lowest quartile) or stratified by severity, except for regular-fat dairy product intake with late-stage prostate cancer risk (HR = 1.37, 95% CI = 1.04–1.82 comparing the highest with lowest quartile) and 2%-fat milk intake with advanced prostate cancer risk (HR = 1.14, 95% CI = 1.02–1.28 comparing the higher than median intake with no intake group). Our findings do not support the previously reported harmful impact of dairy consumption on overall prostate cancer risk among men in the United States.


  • Endorectal MR imaging of prostate cancer: Evaluation of tumor capsular contact length as a sign of extracapsular extension

    by Gustavo Mendez, Bryan R. Foster, Xin Li, Jackilen Shannon, Mark Garzotto, Christopher L. Amling, Fergus V. Coakley


  • Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.

    by Gregory Russell Pond, Guru Sonpavde, Melissa Plets, Catherine M. Tangen, Maha Hussain, Primo Lara, Amir Goldkorn, Mark Garzotto, Philip C. Mack, Celestia S. Higano, et al.

    5079 Background: Prostate specific antigen (PSA) and bone scan changes are often used as components of primary endpoints in phase II trials of mCRPC. However, they do not reliably capture drug activity, as suggested by multiple phase III trials that failed to validate promising activity in phase II trials. Recently, an association between RECIST 1.0 changes and overall survival (OS) in men with mCRPC receiving docetaxel was observed. We externally validated the prognostic impact of RECIST 1.0 changes on OS. Methods: S0421 was a phase III trial in men with mCRPC men treated with docetaxel and prednisone plus either placebo or atrasentan. Individual patient data from both arms of were combined for analysis since no differences in outcomes were observed. Cox proportional hazards regression evaluated the association of RECIST outcomes within 120 days, i.e. unconfirmed partial response (PR), stable disease (SD) and progressive disease (PD) with OS from day 120. The analysis was adjusted for selected major baseline prognostic factors: hemoglobin, alkaline phosphatase, PSA, treatment arm, performance status, visceral disease, progression type, pain and Gleason score. All tests were two-sided and P ≤ 0.05 was considered statistically significant. Results: Of 1038 eligible patients on S0421, 469 had measurable disease. Of these, 377 had RECIST assessments within 120 days after starting therapy. From day 120, 23 patients had PD, 230 had SD, and 73 had ≥ PR (n = 73). Median OS of was 7.1, 13.4 and 16.3 months, respectively (p = 0.004). After adjusting for baseline factors, RECIST changes remained significantly associated with OS (p = 0.002). For every 10% increase in lesion size, the hazard of dying after day 120 increased by 6.3% (95% CI: 2.3% to 10.5%, p = 0.0018), after adjusting for prognostic factors. Conclusions: This analysis provides external validation of the association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel-based chemotherapy. Given that current imaging is increasingly detecting measurable disease, a robust and objective signal of activity represented by RECIST changes should be shown in phase II trials before launching phase III trials.

  • Genomic analysis of prostate cancer.

    by Christine M. Barnett, Michael C. Heinrich, Dylan A. Nelson, Jeong Youn Lim, Carol Beadling, Andrea Warrick, Tanaya Neff, George Thomas, Mark Garzotto, Celestia S. Higano, et al.

    80 Background: The characterization of actionable mutations is a prerequisite for the development of individualized, targeted therapy. We sought to characterize the prevalence of potentially therapeutically actionable mutations in patients with high risk prostate cancer. Methods: 48 samples of formalin fixed paraffin embedded prostatectomy tissue from a neoadjuvant chemotherapy trial (Garzotto M, Cancer 2010 Apr 1;116(7):1699-708) were analyzed. DNA was extracted from microdissected tumor. Tumor DNA was analyzed for 643 common solid tumor point mutations in 53 genes using mass spectroscopy based sequencing (Sequenom MassArray). Low level mutations were validated using ion chip pH based sequencing (Ion Torrent). In addition, PTEN loss and ERG translocations were examined using immunohistochemistry in associated tissue microarrays. Correlation with relapse during 5 years of follow-up was examined in exploratory analyses of the potential clinical relevance of the genetic alterations examined. Results: Of the 40 tumors evaluable for mutations, 10% had point mutations in potentially actionable cancer genes. Of the 45 tumors evaluable for IHC, 36% had PTEN loss (6% with a heterogenous pattern) and 40% had ERG rearrangement (2% with heterogeneous pattern). Individual mutations were not frequent enough to determine associations with progression. Using Kaplan-Meier analysis with a log-rank test, the 16 patients who had PTEN loss had a significantly shorter median progression free survival, 19 vs. 106 months (p = .01). Conclusions: This study confirms that point mutations in the most common cancer regulatory genes in prostate cancer are rare. However, the PIK3CA/AKT pathway was mutated in 10% of our samples. While point mutations alone did not have a statistically significant effect on relapse, PTEN loss was associated with an increased relapse in high risk prostate cancer treated with chemotherapy followed by surgery. It is yet unclear if the 16 weeks of chemotherapy played a role in selecting for tumors with these biologic features, and this will therefore be the subject of future investigations. [Table: see text]

  • Open Access

    Androgen deprivation therapy for prostate cancer: not so simple

    by Nicholas N Tadros, Mark Garzotto

    AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.


  • Contemporary Management of High-risk Localized Prostate Cancer

    by Mark Garzotto, Arthur Y. Hung

    The management of high-risk, localized prostate cancer remains a formidable challenge despite significant technical advances in surgery and radiation therapy. Treatment outcomes of radiation therapy are improved by the addition of adjuvant androgen deprivation therapy, whereas, with surgery, oncologic results are enhanced with either postoperative radiation therapy or androgen deprivation therapy in select cases. In high-risk prostate cancer, disease recurrence after primary therapy may occur at either distant or local sites. Ongoing studies are in the process of evaluating systemic therapy for the eradication of local and micrometastatic disease. Neoadjuvant therapies offer the opportunity to maximize local control as a path to improved outcomes and critically evaluate agent effectiveness in the target tissue. The treatment for high-risk localized prostate cancer is in evolution. It is likely that the development of effective strategies based on understanding prostate tumor biology will lead to significant advances in the treatment of this disease.